Quand tu fais ta première nasofibro

Good to see RADICALS-HD in print. THanks to numerous colleagues and collaborators over 20 years authors.elsevier.com/sd/article/S01…

🔥PLENARY Session #ASCO24🔥 Perioperative chemotherapy (FLOT) to neoadjuvant chemoradiation (CROSS) in patients with adenocarcinoma of the esophagus 🔎 ESOPEC phase III trial, 438 patients 👉R0 180 vs 171 👉pCR 17 vs 10% 👉mOS 66 vs 37 mo 👉3yr OS: 57.4 vs 50.7% 🧐FLOT improves

Locoregional Ablative Radiation Therapy for Patients With Breast Cancer Unsuitable for Surgical Resection. practicalradonc.org/article/S1879-…

I love Twitter 😅😂

Tell me again why we can’t use renal SBRT in the UK?!? 100% local control is hard to beat. Masterclass by Shankar Siva #ASTRO24

Urologists in 2026 when sbrt takes over #handitover #comingforbladdernext #donth8ablate #radonc

Do all early-stage breast cancer patients need axillary surgery? The INSEMA trial challenges this long-standing practice, showing that skipping sentinel lymph node biopsy (SLNB) may be safe for select patients. ☢️ plays a key role. Let’s dive into the data. 🧵 1/13#RadOnc

7/ The role of ☢️: •For patients who skipped axillary surgery, incidental radiation doses to the axilla during whole-breast radiotherapy provided sufficient regional control. •Axillary level I received ~85% of the prescribed dose for the breast, while level II received ~15%.

Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

ESOPEC trial - Game changer for resectable esophageal adenocarcinoma Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

🚨 Who needs more than standard ☢️ + ADT in high-risk prostate cancer? 🚨OncoAlert 🔎 Objective: Identify HRLPC patients with poor outcomes on ☢️+ long-term ADT 🧪 Methods: ✅ 3,604 👥 from 10 RCTs ✅ Evaluated Metastasis-Free Survival (MFS) & Overall Survival (OS) ✅ Risk

Contrer à cette hauteur à 2 mains, c'est athlétiquement irréel, c'est Diamant Blazi 🇫🇷

Incredible prognostic power of PSMA PET from the updated PROMISE large international registry (PPP2): 3 and 5-yr survival data. Superior to NCCN risk score. Data across initial stage, biochemical recurrence, "non-metastatic" castration-resistant, mSPC, MCRPC !! Just out in

📢 STORM trial breaking results at #ESTRO25! 🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa. 🧬 ENRT+MDT: ✅ Superior bRFS (57% vs 41%, p=0.014) ✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006) ✅ Superior MFS (76% vs 63%, p=0.06) ❌ No increase in ≥G2 GU/GI toxicity

Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios. ja.ma/4jePW1F

#ASCO25 NEJM BREAKWATER: Encorafenib + cetuximab + mFOLFOX6 vs standard care in 1L BRAF V600E mCRC PFS➡️12.8 vs 7.1 mo✅️ OS➡️ 30.3 vs 15.1 mo✅️👏 💥For one of the hardest-to-treat mCRC subtypes, this triplet shows substantial survival benefit. nejm.org/doi/full/10.10…

🚨Epidemiology of High-risk Biochemical Recurrence After Primary #ProstateCancer Treatment🚨 🙍‍♂️🙍‍♂️17K population-based study 👉 Using BCR risk groups continues to show promise to personalize treatment intensity for future patients European Urology Oncology 🔗shorturl.at/LuvYZ

Induction-concurrent chemotherapy does not significantly improve progression-free survival compared with concurrent-adjuvant chemotherapy in high-risk N2–3 nasopharyngeal carcinoma. ja.ma/3JqAGCH

🔥 PCS-9: SBRT + ENZA Doubles Disease Control in Oligometastatic CRPC OncoAlert Fabio Cury 🎯 Objective • Evaluate whether adding SBRT to ADT + enzalutamide ⬆️ outcomes in oligometastatic CRPC (≤5 mets) 🏥 Methods • Ph 2, randomized, 13 Canadian centers. • 100 men with